Medpace Holdings, Inc.
About Medpace Holdings, Inc.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $2.5B
- Net income
- $451.1M
- Total assets
- $2.0B
- Market cap
- $13.0B
- Gross margin
- 30.1%
- Operating margin
- 21.1%
- Net margin
- 17.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $2.5B
- Cost of revenue
- $1.8B
- Gross profit
- $760.6M
- Operating expenses
- $225.7M
- Operating income
- $534.9M
- Income tax
- $91.3M
- Net income
- $451.1M
- EPS (basic)
- $15.64
- EPS (diluted)
- $15.28
Balance sheet
- Total assets
- $2.0B
- Current assets
- $989.6M
- Total liabilities
- $1.5B
- Current liabilities
- $1.3B
- Shareholders’ equity
- $459.1M
Cash flow
- Operating cash flow
- $713.2M
- Investing cash flow
- -$31.1M
- Financing cash flow
- -$860.4M
- Net cash flow
- -$172.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $13.0B
- P/E ratio
- 30.0
- EPS (diluted)
- $15.28
- Shares outstanding
- 28.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 11, 2016
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $451.1M in FY2025.
- Revenue grew 121% from FY2021 to FY2025.
- Gross margin of 30.1%, net margin 17.8%.
- Trading 26% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 30.0.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Medpace Holdings, Inc..
Write a review
News about Medpace Holdings, Inc.
News & sentiment via Polygon.io
